Kura Oncology, Inc. (NASDAQ:KURA) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET

Company Participants

Troy Wilson – Chairman and Chief Executive Officer

Tom Doyle – Senior Vice President, Finance and Accounting

Pete De Spain – Senior Vice President, Investor Relations and Corporate Communications

Conference Call Participants

Jonathan Chang – SVB Securities

Peter Lawson – Barclays Corporate & Investment Bank

Jonathan Ofertiago – Credit Suisse

Roger Song – Jefferies

Reni Benjamin – JMP Securities

Eva Privitera – Cowen, Inc.

Operator

Good day and welcome to the Kura Oncology First-Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today's presentation there will be an opportunity to ask questions. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Mr. Pete De Spain, Senior Vice President of Investor Relations. Please go ahead.

Pete De Spain

Great, thank you Ren. Good afternoon and welcome to Kura Oncology’s first-quarter 2022 conference call. Joining me on the call are Dr. Troy Wilson, our President and Chief Executive Officer, and Tom Doyle, our Senior Vice President of Finance and Accounting. Dr. Stephen Dale, our Chief Medical Officer, is also with us and available to answer questions. Before I turn the call over to Dr. Wilson, I would like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC, which are available from the sec or on the Kura Oncology website for information concerning risk factors that could affect the company. With that, I'll now turn the call over to Troy.

Troy Wilson

Thank you, Pete. And thank you all for joining us this afternoon. Despite what continues to be a challenging, broader market environment, we continue to operate from a position of strength here at Kura, armed with 3 independent drug development programs, a strong experienced team, a well-designed clinical development strategy, and a cash runway through 2024. Now, as we approach a series of important catalysts driven by completion of enrollment in the Phase 1b study of our Menin Inhibitor, Ziftomenib. And culminating in top-line data next quarter and a full data presentation in the fourth quarter. As mentioned, I'm pleased to report, we recently completed enrollment of the patients in the Phase 1b portion of KOMET -001, required to identify a recommended Phase 2 dose for Ziftomenib.